Krystal Biotech, Inc. (KRYS) Stock Analysis

Earnings Beat May Change The Case For Krystal Biotech (KRYS) Stock

Tue, November 3, 2026 at 5:10 AM UTC 2 min read

Krystal Biotech reported a Q3 2026 net income of US$63.07 million and diluted EPS of US$2.05, surpassing consensus estimates. The company announced a US$400 million share repurchase authorization with no expiration date, reflecting confidence in its VYJUVEK product, which saw a 30% year-over-year revenue increase. While the earnings beat strengthens the investment narrative, execution risks remain, particularly regarding international launches and managing R&D costs alongside product contributions.

Read full article →

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

Mon, October 26, 2026 at 1:00 PM UTC 4 min read

Analysts project that Krystal Biotech, Inc. (KRYS) will report a decline in earnings in the upcoming financial results, raising concerns about the company's growth trajectory. This anticipated downturn could impact investor sentiment and stock performance, as it may indicate challenges in product development or market demand. Investors should closely monitor the earnings report for insights into the company's financial health and future prospects.

Read full article →